Monitoramento de Quimioterapia Neoadjuvante de Câncer de Mama Usando Estimativa de Pressão Auxiliada por Subharmônico 3D

Inclusion Criteria:

• Provide signed and dated informed consent form
• Willing to comply with all study procedures and be available for the duration of the study
• At least 21 years old
• Be diagnosed with breast cancer (T1 or greater LABC, any N and M0)
• Be scheduled for neoadjuvant chemotherapy
• Be medically stable
• Be conscious and able to comply with study procedures
• If a female of child-bearing potential, must have a negative urine pregnancy test

Exclusion Criteria:

• Males

• Females who are pregnant or nursing

• Patients with other primary cancers requiring systemic treatment

• Patients with any distal metastatic disease

• Patients undergoing neoadjuvant endocrine therapy

• Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:

  • Patients on life support or in a critical care unit;
  • Patients with unstable occlusive disease (e.g., crescendo angina);
  • Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia;
  • Patients with uncontrolled congestive heart failure (New York Heart Association [NYHA] Class IV);
  • Patients with recent cerebral hemorrhage;
  • Patients who have undergone surgery within 24 hours prior to the study sonographic examination

• Patients with known hypersensitivity or allergy to any component of Definity

• Patients with unstable cardiopulmonary conditions or respiratory distress syndrome

• Patients with uncontrollable emphysema, pulmonary vasculitis, pulmonary hypertension or a history of pulmonary emboli